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A B S T R A C T
Purpose
Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
selective for both EGFR-TKI sensitizing (EGFRm) and T790M resistance mutations. AURA
(NCT01802632) is a phase I/II clinical trial to determine the dose, safety, and efficacy of osimertinib.
This article reports the results from the phase II extension component.
Patients and Methods
Patients with EGFR-TKI–pretreated EGFRm- and T790M-positive advanced non–small-cell lung
cancer (NSCLC) received once-daily osimertinib 80 mg. T790M status was confirmed by central
testing from a tumor sample taken after the most recent disease progression. Patients with
asymptomatic, stable CNS metastases that did not require corticosteroids were allowed to enroll.
The primary end point was objective response rate (ORR) by independent radiology assessment.
Secondary end points were disease control rate, duration of response, progression-free survival
(PFS), and safety. Patient-reported outcomes comprised an exploratory objective.
Results
In total, 201 patients received treatment, with a median treatment duration of 13.2 months at the
time of data cutoff (November 1, 2015). In evaluable patients (n = 198), ORRwas 62% (95%CI, 54%
to 68%), and the disease control rate was 90% (95% CI, 85 to 94). Median duration of response in
122 responding patients was 15.2 months (95% CI, 11.3 to not calculable). Median PFS was
12.3 months (95% CI, 9.5 to 13.8). The most common possibly causally related adverse events
(investigator assessed) were diarrhea (43%; grade $ 3, , 1%) and rash (grouped terms; 40%;
grade$ 3,, 1%). Interstitial lung disease (grouped terms) was reported in eight patients (4%; grade
1, n = 2; grade 3, n = 3; grade 5, n = 3).
Conclusion
In patients with EGFRm T790M advanced NSCLC who progress after EGFR-TKI treatment, osi-
mertinib provides a high ORR, encouraging PFS, and durable response.
J Clin Oncol 35. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Epidermal growth factor receptor (EGFR) tyro-
sine kinase inhibitors (TKIs) are the recom-
mended first-line treatment of patients with
advanced lung cancer that harbors an activating
EGFR mutation (EGFRm),1,2 which is supported
by results from several phase III studies.3-8 De-
spite high initial responses to first-line EGFR-
TKIs and a median progression-free survival
(PFS) of 10 to 14 months, resistance eventually
develops in most, if not all, patients. The most
common mechanism of acquired resistance to
EGFR-TKIs, the EGFR p.Thr790Met point mu-
tation (T790M), can be detected in 50% to 60% of
tissue biopsy samples taken after acquired
resistance.9-12
Osimertinib is an oral, irreversible EGFR-
TKI selective for both EGFRm and T790M re-
sistance mutations.13 The phase I component of
the osimertinib AURA (NCT01802632) study
showed clinical activity across oral doses of 20 to
240 mg/day.14 The optimal dose chosen for
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further phase II evaluation was 80 mg once daily. The phase I study
results suggested that both patients with T790M-positive non–
small-cell lung cancer (NSCLC) and patients with T790M not
detected derive benefit from osimertinib treatment but with
a much higher response rate in patients with T790M-positive
disease (objective response rate [ORR], 61% v 21%). AURA ex-
tension is the phase II component of the AURA study. We report
the treatment outcomes, including ORR, by blinded independent
central review (BICR), duration of response (DoR), and PFS of
patients in the AURA extension phase II study.
PATIENTS AND METHODS
Study Design and Participants
The AURA study was a phase I/II, open-label, multicenter study of
osimertinib in patients with advanced NSCLC who had progressed after
therapy with an EGFR-TKI agent (with or without additional anticancer
regimens). Patients were at least 18 years of age ($ 20 years in Japan) with
a histologically or cytologically confirmed diagnosis of NSCLC that har-
bored confirmed EGFR-TKI sensitizing EGFRm and were enrolled across
46 study centers in Japan (16), the United States (seven), South Korea
(four), Australia (three), France (three), Germany (three), Spain (three),
Italy (three), Taiwan (two), and the United Kingdom (two).
The AURA study consisted of dose escalation and dose expansion in
phase I with the capsule formulation of osimertinib (methods and pre-
liminary results have been previously reported)14 and a phase II extension
component with the tablet formulation at the recommended phase II
80-mg once-daily dose. Two cohorts comprised the phase II extension
component: patients whose disease had progressed (confirmed by ra-
diologic documentation) either after only one prior therapy with an EGFR-
TKI (second line) or after treatment with at least two lines of prior therapy,
including at least one EGFR-TKI (third line or more).
Eligibility criteria are provided in detail in the Appendix (online only).
Briefly, patients were required to have a WHO performance status of 0 to 1
and acceptable organ function. Patients with CNS metastases could be en-
rolled if the disease was asymptomatic, stable, and not requiring cortico-
steroids for at least 4 weeks before the first dose. Prospective confirmation of
T790Mmutation status was by a central laboratory that used the cobas EGFR
Mutation Test (Roche Molecular Systems, Pleasanton, CA; Appendix) from
a tissue biopsy specimen taken after disease progression on the most recent
treatment regimen (irrespective of whether EGFR-TKI or chemotherapy).
All participating sites required approval from the independent in-
stitutional review board/independent ethics committee. The study was
performed in accordance with the ethical principles that have their origin
in the Declaration of Helsinki and that are consistent with International
Conference on Harmonization/Good Clinical Practice and applicable
regulatory requirements. All patients provided written informed consent
before their participation in the study. The protocol was designed by the
sponsor (AstraZeneca) and the study investigators.
Procedure
Eligible patients received 80 mg osimertinib orally once daily and
continued treatment until Response Evaluation Criteria in Solid Tumors
version 1.1 (RECIST1.1)–defined progression or until a treatment dis-
continuation criterion was met. Patients could continue to receive osi-
mertinib beyond RECIST1.1–defined progression if they continued to
show clinical benefit as judged by the investigator. If osimertinib was
discontinued for reasons other than disease progression, the patient
continued response assessment every 6 weeks until disease progression.
The primary end point of the AURA phase II extension study was
ORR by BICR. Secondary end points were DoR, disease control rate
(DCR), tumor shrinkage, PFS, overall survival (OS), safety, tolerability, and
pharmacokinetics. Collection of patient-reported outcomes (PROs) and
quality of life were exploratory objectives. DoR, DCR, tumor shrinkage,
and PFS were determined by using RECIST1.1 assessed by BICR. Adverse
events (AEs) were graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events (version 4). The Ap-
pendix provides further details on procedures related to AEs and the
collection of PROs.
Statistical Analysis
The full analysis set was defined as all patients enrolled who received
at least one dose of study treatment. The evaluable for response analysis set
was defined as all patients who received at least one dose of study treatment
and had measurable disease at baseline according to BICR. CNS efficacy
was assessed in an evaluable for CNS response analysis set, which included
patients with at least one measurable CNS lesion on baseline brain scan
(RECIST1.1) by BICR (assessed by neuroradiologists). The primary ef-
ficacy end point variable ORR by BICR (according to RECIST1.1) was
defined as the percentage of patients with at least one visit response of
complete response or partial response confirmed at least 4 weeks later.
(Definitions of PFS and DoR are provided in the Appendix.) No formal
statistical analysis was done. The study was sized to recruit approximately
175 patients to estimate an ORR with 95% CI within 6 8% and to ad-
equately assess safety and tolerability.
Statistical analyses were performed by Pharmaceutical Product De-
velopment (Wilmington, NC). All calculations were performed with SAS
9.2 software (SAS Institute, Cary, NC) unless otherwise stated. We report
a November 1, 2015, data cutoff.
RESULTS
Demographics
Between May 14, 2014, and November 1, 2015, 401 patients
were screened, and 327 patients’ samples were eligible for T790M
testing, of which 324 (99%) gave a valid test result; 207 (64%) had
positive test results for T790M. The T790M detection rate did not
vary by last prior EGFR-TKI treatment (gefitinib, 69%; erlotinib,
68%; afatinib, 68%; Appendix Table A1, online only).
Two hundred one patients received osimertinib treatment
(61 as second-line therapy and 140 as third-line or more therapy;
Fig 1); three patients had nomeasurable disease at baseline by BICR
and were excluded from the evaluable for response set (n = 198).
Baseline characteristics are listed in Table 1. Twenty-five patients
were included in a CNS response analysis set.
Duration of Treatment
At the time of analysis, the median duration of exposure was
13.2 months (range, 0.1 to 17.6 months). By investigator assess-
ment, 106 patients were known to be alive after radiologic pro-
gression of whom 79 continued to receive osimertinib for at least
7 days after their first radiologic progression for a median duration
of 3.4 months (Fig 1). Forty-eight of the 106 patients received at
least one subsequent cancer therapy after progression (Fig 1).
Efficacy
Tumor response. One hundred ninety-eight patients were
evaluable for response by BICR. ORR was 62% (122 of 198 pa-
tients; 95% CI, 54 to 68), and DCR was 90% (179 of 198 patients;
95% CI, 85 to 94). ORRs ranging from 53% to 68% were observed
across all presented predefined subgroups (Fig 2). ORRs were
similar between the second-line and third-line or more cohorts
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(62% and 61%) and by common EGFR-TKI sensitizing mutation
status (exon 19 deletion, 64%; L858R, 57%), respectively (Fig 2).
Post hoc analyses of ORR by last prior EGFR-TKI treatment were as
follows: gefitinib, 68% (64 of 94 patients; 95% CI, 58 to 77);
erlotinib, 57% (56 of 99 patients; 95% CI, 46 to 67); and afatinib/
dacomitinib, 50% (two of four patients; 95% CI, 7 to 93).
Overall, 99 (81%) of 122 responders had a documented initial
response at their first scheduled follow-up RECIST1.1 scan at 6 6
1 weeks. Tumor shrinkage was seen in the majority of patients
(94%; Fig 3A). The mean best percentage change in target lesion
size from baseline was 242.7%.
Of the 122 patients deemed to have an objective response, 46
(38%) had subsequently progressed or died by the time of analysis.
The median DoR was 15.2 months (95% CI, 11.3 to not calculable
[NC]; range, 1.4 to 15.3 months). The proportion of patients with
an objective response who subsequently progressed or died was
similar by last EGFR-TKI treatment received before osimertinib
(gefitinib, 22 [34%] of 64; erlotinib, 23 [41%] of 56; afatinib/
dacomitinib, one [50%] of two).
PFS and OS. At the time of data cutoff, 107 (53%) of 201
patients had progressed or died (by BICR). One hundred four of
these patients were on treatment at the time of progression; three had
discontinued osimertinib before progression and, therefore, were not
censored. Median PFS (by BICR) was 12.3 months (95% CI, 9.5 to
13.8); 11.0 months (95% CI, 6.7 to NC), and 12.4 months (95% CI,
9.5 to 15.5) in the second-line and third-line or more cohorts,
respectively (Fig 4A). The proportion of patients progression free at
6, 9, and 12 months was 70%, 58%, and 52%, respectively.
Subset analysis of PFS by EGFRm status before the start of the
study showed a nonsignificant trend toward longer PFS in patients
who harbored an exon 19 deletion (median, 12.5 months; 95% CI,
9.7 to NC) compared with L858R (median, 9.6 months; 95% CI,
6.9 to 13.8; Fig 4B). Similarly, a nonsignificant trend toward longer
PFS was observed in Asian versus non-Asian patients (median,
12.6 months [95% CI, 9.7 to 16.6] v 9.7 months [95% CI, 7.0 to
13.8], respectively; Fig 4C). Median PFS by last prior EGFR-TKI
treatment was 12.6 months (95% CI, 9.5 to NC) for gefitinib and
11.0 months (95% CI, 6.9 to 13.8) for erlotinib (Fig 4D).
Median PFS generally was consistent across other subgroups
analyzed: age at screening (, 65 v $ 65 years), smoking status
(never v ever), last treatment before osimertinib (EGFR-TKI
v non–EGFR-TKI), immediate prior EGFR-TKI treatment
(, 30 days before osimertinib v$ 30 days before osimertinib), and
duration of most recent EGFR-TKI treatment (, 6 v$ 6 months;
Appendix Table A2, online only).
At the time of data cutoff, 54 patients (27%) had died; hence,
the median OS was not reached (95% CI, 16.4 to NC). The median
follow-up for OS was 13.8 months. One-year survival rate was 79%
(95% CI, 72 to 84; Appendix Fig A1, online only).
Symptom resolution. Data from European Organization for
Research and Treatment of Cancer questionnaires QLQ-LC13 and
QLQ-C30 showed that patients had consistent and sustained
improvements in key lung cancer symptoms, including dyspnea,
cough, chest pain, and pain in arm or shoulder (Appendix Fig A2,
online only). Sustained improvements in global health status and
physical functioning domains also were recorded.
Osimertinib activity in patients with CNS metastases. Seventy-
four patients had CNS metastases at entry. Median PFS was shorter in
patients with CNS metastases than in those without (median,
7.1 months [95% CI, 4.2 to 12.3] v 13.7 months [95% CI, 11.0 to NC],
respectively; Appendix Fig A3, online only). In the CNS response
analysis set, theORRwas 64% (16 of 25 patients; 95%CI, 43 to 82); four
patients experienced a complete response and 12 patients a partial
response. Tumor shrinkage was seen in the majority of patients (Fig 3B)
Assigned to and received
study treatment
  Second-line cohort
  Third-line or more  cohort  (n = 140)
(n = 201)
(n = 61)
Screened*
(N = 401)
Not assigned to study treatment
Tumor not centrally confirmed EGFR T790M
    mutation positive
 No radiological documentation of disease prog-
    ression while receiving prior EGFR-TKI treatment
 Did not have at least one lesion that was suitable
    for accurate repeated measurement
 Patients were excluded for other reasons
(n = 200)
(n = 158)
(n = 5)
(n = 5)
(n = 32)
Progressed (by investigator assessment) or died by DCO
 Known to be alive after radiologic progression
 Died
 Received osimertinib after progression
 Received at least one subsequent cancer therapy after progression
     Platinum-containing chemotherapy
     Cytotoxic chemotherapy (no platinum)
     EGFR-TKI
     PD1/PD-L1 agent
     Cytotoxic chemotherapy plus an EGFR-TKI
     Osimertinib plus another therapy
     EGFR-TKI plus a PD1/PD-L1 agent
  Discontinued osimertinib after progression
     Adverse event
     Objective disease progression
     Other
     Patient decision
(n = 118)
(n = 106)
(n = 12)
(n = 79)
(n = 48)
(n = 18)
(n = 16)
(n = 15)
(n = 8)
(n = 3)
(n = 3)
(n = 1)
(n = 51)
(n = 5)
(n = 32)
(n = 10)
(n = 4)
Not progressed (by investigator assessment) or died by DCO
 Censored RECIST progression or death†
 Progression free at time of analysis‡
 Lost to follow-up§
 Withdrawn consent§
 Discontinued study§
(n = 83)
(n = 1)
(n = 78)
(n = 0)
(n = 4)
(n = 0)
Fig 1. Patient disposition. All treatment decisions were based on investigator interpretation of patient disease status. *Informed consent received. Patients could have
had more than one reason for not being assigned to treatment and, hence, would be counted more than once. †Response Evaluation Criteria in Solid Tumors (RECIST)
progression event occurred 19 weeks after last evaluable RECIST assessment. ‡Includes patients known to be alive with no evaluable baseline RECIST assessment
(censored at day 0). §Patients at last evaluable RECIST assessment. DCO, data cutoff; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
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Safety
Nearly all patients reported at least one AE (199 [99%] of
201), with 185 (92%) reporting at least one AE possibly casually
related to osimertinib treatment. A summary of safety and all-cause
AEs are listed in Appendix Tables A3 and A4 (online only). The
most common possibly causally related AEs (by investigator as-
sessment) were diarrhea, rash (grouped terms), paronychia
(grouped terms), and dry skin (grouped terms; Table 2). The
Table 1. Baseline Characteristics of Study Patients (full analysis set)
Characteristic
Second Line,
No. (%) Third Line or More, No. (%)
Total,
No. (%)
No. of patients 61 140 201
Age, years
Mean (SD) 62.6 (10) 60.9 (11) 61.4 (11)
Median (range) 61 (45-89) 63 (37-84) 62 (37-89)
Sex
Male 20 (33) 48 (34) 68 (34)
Female 41 (67) 92 (66) 133 (66)
Ethnicity
White 24 (41) 52 (37) 76 (38)
Asian 32 (54) 82 (59) 114 (57)
Black or African American 0 1 (1) 1 (, 1)
Other 1 (2) 3 (2) 4 (2)
Not reported* 2 (3) 2 (1) 4 (2)
Smoking status
Never 41 (67) 93 (66) 134 (67)
Former 20 (33) 42 (30) 62 (31)
Current 0 5 (4) 5 (2)
WHO performance status
0 25 (41) 43 (31) 68 (34)
1 36 (59) 96 (69) 132 (66)
2 0 1 (1) 1 (, 1)†
Histology
Adenocarcinoma 60 (98) 135 (96) 195 (97)
Adenosquamous carcinoma 0 1 (1) 1 (, 1)
Other 1 (2) 4 (3) 5 (2)
EGFR T790M mutation by cobas central test 59 (97) 138 (99) 197 (98)‡
EGFR mutations co-occurring with
T790M by cobas central test
Exon 19 deletion 44 (72) 98 (70) 142 (71)
L858R 16 (26) 35 (25) 51 (25)
G719X 1 (2) 3 (2) 4 (2)
S768I 0 3 (2) 3 (1)
Exon 20 insertion 1 (2) 1 (1) 2 (1)
T790M only 0 5 (4) 5 (2)
Overall disease classification
Metastatic 59 (97) 138 (99) 197 (98)
Locally advanced 2 (3) 2 (1) 4 (2)
Metastases
CNS§ 14 (23) 60 (43) 74 (37)
Visceral 50 (82) 123 (88) 173 (86)
Median No. of prior regimens (range) 1 3 (2-11) 2 (1-11)
Prior treatment
First-generation EGFR-TKIs
Gefitinib 32 (52) 85 (61) 117 (58)
Erlotinib 28 (46) 88 (63) 116 (58)
Second-generation EGFR-TKIs
Afatinib 0 (0) 36 (26) 36 (18)
Afatinib + cetuximab 4 (3) 4 (2)
Dacomitinib 1 (2) 3 (2) 4 (2)
Other EGFR-TKI 0 5 (4) 5 (2)
Platinum-containing doublet chemotherapy 0 122 (87) 122 (61)
Platinum-containing doublet chemotherapy + bevacizumab 0 25 (18) 25 (12)
Abbreviations: EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
*Some countries do not allow collection of ethnicity data.
†Protocol deviation: inclusion criteria state that patients should have a WHO performance status of 0 or 1.
‡Three patients with EGFR T790Mmutation status not detected (negative) and one patient not centrally tested entered the study; consequently, these were considered
important protocol deviations. Of the three patients with no T790M detected by central testing, one had detectable exon 19 deletion, one had detectable L858R, and one
had detectable exon 19 deletion/S768I.
§CNS metastases were determined programmatically from baseline data: patients with a CNS metastatic site, those who reported prior radiotherapy in anatomic
locations unequivocally in the CNS, and/or those who reported surgical excision of tumor from anatomic locations unequivocally in the CNS.
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majority of these possibly causally related AEs were mild (grade 1
in severity).
Interstitial lung disease (ILD) grouped term AEs were re-
ported in eight patients, all deemed possibly causally related (4%;
grade 1, n = 2; grade 3, n = 3; grade 5, n = 3). Three AEs resolved,
two were ongoing at the time of data cutoff, and three were re-
ported as fatal (two reports of ILD and one of pneumonitis). Three
(4%) of 76 AEs were reported in white patients, three (9%) of 35 in
Japanese patients, and two (4%) of 45 in non-Japanese Asian
patients. The median time to onset for ILD grouped term AEs was
5.1 months. QT prolongation AEs were recorded in six patients
(3%; grade 1, n = 5; grade 2, n = 1), possibly causally related in
three patients (2%; grade 1, n = 2; grade 2, n = 1). In two reports,
QT prolongation led to a dose reduction.
Forty-three patients (21%) experienced AEs that led to dose
interruption of osimertinib treatment, and 10 patients (5%) ex-
perienced AEs that led to dose reduction. Nine patients (3%)
discontinued osimertinib treatment as a result of possibly causally
related AEs (seven because of ILD grouped terms [discontinuation
mandated by protocol]; one because of neutrophil count decrease;
and one because of decreased appetite, asthenia, diarrhea, and
vomiting).
DISCUSSION
In this study, oral osimertinib 80 mg once daily resulted in a high
ORR and DCR with significant DoR and PFS in patients with
EGFR-TKI–resistant EGFRm lung cancer with tumors harboring
T790M. This finding is consistent with the previous analysis of
the AURA phase I study that demonstrated high response rates
across the 20- to 240-mg dose range of osimertinib in patients
with T790M-positive tumors.14 The current study demonstrates
a median PFS of 12.3 months and a DoR of 15.2 months in
responding patients. The phase II study AURA2 (NCT02094261
[independent phase II study with a similar design conducted in
different centers]) demonstrated a similar ORR and PFS, which
further confirms the efficacy of osimertinib in patients who
0 20 40
ORR (95% CI)
60 80 100
ORR (95% CI)
62 (54 to 68)Overall (n = 198 ) 
Treatment cohort
Second line (n = 61)
Third line or more (n = 137)
Ethnicity
Asian (n = 113)
Non-Asian (n = 79) 
61 (52 to 68)
57 (47 to 66)
68 (54 to 80)
66 (49 to 80)
59 (51 to 68)
66 (53 to 77)
53 (41 to 64)
67 (58 to 75)
55 (39 to 70)
63 (55 to 71)
64 (55 to 72)
57 (42 to 71)
63 (54 to 72)
60 (48 to 70)
63 (50 to 75)
61 (52 to 69)
67 (58 to 76)
54 (43 to 66)
62 (49 to 74)
61 (53 to 70)
Sex
Male (n = 65)
Female (n = 133) 
Age at screening
< 65 years  (n = 114)
≥ 65 years  (n = 84) 
Co-occuring EGFR-TKI-sensitizing mutation
before start of study
Exon 19 deletion (n = 140)
L858R (n = 49) 
Duration of most recent prior EGFR-TKI treatment
< 6 months (n = 42)
≥ 6 months (n = 156)
CNS metastases at entry
Yes (n = 74)
No (n = 124) 
Smoking history
Never (n = 133)
Ever (n = 65) 
Last treatment before study start
EGFR-TKI (n = 157)
< 30 days before first dose of osimertinib (n = 104)
≥ 30 days before first dose of osimertinib (n = 53)
Not EGFR-TKI (n = 41) 
Fig 2. Objective response rate (ORR) by central
review by subgroup in the evaluable for response
set. The 95% CIs were calculated by using Clopper-
Pearson exact method for binomial proportions. The
gray band represents the 95% CI for the overall
patient ORR. EGFR, epidermal growth factor re-
ceptor; TKI, tyrosine kinase inhibitor.
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harbor T790M.15 We also report encouraging systemic PFS with
osimertinib in patients with CNS metastases and a high CNS
response (64%) in those with measurable CNS lesions. The latter
is particularly relevant because new pharmacologic strategies are
needed to treat brain metastases given the long-term compli-
cations of brain radiation.16
The standard recommendation for patients with EGFRmwho
progress after first-line EGFR-TKI treatment is chemotherapy, for
which the maximum PFS reported to date is , 6 months.17 For
these patients, alternative treatment strategies have been explored.
A study of treatment with paclitaxel and afatinib resulted in an
ORR of 32% and PFS of 5.6 months.18 In a phase II study that
evaluated afatinib in combination with cetuximab, the response
rate in patients with T790M-positive tumors was 32% and the
median PFS 4.7 months.19 However, a high rate of grade 3 (44%)
and 4 (2%) AEs were reported with this combination. The ORR,
PFS, and safety profile with osimertinib in both the AURA ex-
tension and the AURA2 studies compare favorably with historical
results. These data support the current recommendation of osi-
mertinib for the treatment of patients with T790M-positive ad-
vanced NSCLC after progression with prior EGFR-TKI therapy.1
The response rates to osimertinib were similar across all
patient subgroups regardless of the line of therapy or the specific
prior EGFR-TKI treatment they had received. Of note, some
patients had received many (up to 11) lines of cancer therapy
before osimertinib. The response rate and PFS were numerically,
although not statistically, higher for patients with co-occurring
T790M and EGFR exon 19 deletion–activating mutations com-
pared with those with co-occurring T790M and EGFR L858R
mutations documented before the study start. Prior studies of
early-generation EGFR-TKIs (gefitinib, erlotinib, and afatinib)
demonstrated greater clinical benefit in patients who harbored
an EGFR exon 19 deletion than in patients with an L858R
mutation.20,21 We also observed a numerically higher response rate
and longer PFS in Asian patients treated with osimertinib, similar
to previous observations with early-generation EGFR-TKIs.3-6,8,22
The reasons behind these observations are not clear because prior
pharmacokinetic analyses demonstrated that osimertinib exposure
is similar in both Asian and non-Asian patients.23
Osimertinib was well tolerated and associated with a low
incidence of discontinuations and dose reductions as a result of
possibly causally related AEs. Osimertinib was associated with
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Fig 3. Best percentage change from baseline in target lesion size by central review in (A) the evaluable for response set and in (B) the CNS response analysis set. The line
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symptomatic improvements, and PRO data in the AURA extension
suggest that patients treated with osimertinib show benefits in
symptoms, functioning, and health status/quality of life from
baseline assessments.
ILD was observed in eight patients (4%), and osimertinib-
associated ILD was observed in both white and Asian patients. The
mechanistic basis and risk factors that led to osimertinib-
associated ILD remain unclear. Presently, patients in whom ILD
develops should discontinue osimertinib therapy and receive ap-
propriate supportive care.
For the AURA extension, central confirmation of T790M was
carried out by using tumor tissue samples. In a recent study that
analyzed plasma-derived circulating tumor DNA as a biomarker
for osimertinib response, Oxnard et al24 concluded that patients
positive for T790M in plasma have outcomes with osimertinib
equivalent to patients with positive tissue-based assay results,
which highlights the feasibility of plasma testing for selecting
patients for osimertinib treatment. Recently, plasma-based
T790M testing was approved by the US Food and Drug
Administration.25
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Fig 4. Progression-free survival (PFS) by blinded independent central review (full analysis set) by (A) line of therapy, by (B) co-occurring epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI)–sensitizingmutation documented before start of study, (C) by ethnicity (Asian and non-Asian), and (D) by last prior EGFR-TKI treatment
(gefitinib, erlotinib). Tick marks indicate censored observations. NC, not calculable.
Table 2. Most Common Possibly Causally Related Adverse Events
Possibly Causally Related Adverse Event*
Grade, No. (%)
1 2 $ 3 Total
Diarrhea 74 (37) 11 (5) 1 (, 1) 86 (43)
Rash (grouped terms) 67 (33) 12 (6) 1 (, 1) 80 (40)
Paronychia (grouped terms) 46 (23) 17 (8) 0 63 (31)
Dry skin (grouped terms) 56 (28) 6 (3) 0 62 (31)
Stomatitis 21 (10) 6 (3) 0 27 (13)
Pruritus 21 (10) 6 (3) 0 27 (13)
Platelet count decreased 23 (11) 0 2 (1) 25 (12)
Nausea 18 (9) 3 (1) 1 (, 1) 22 (11)
Decreased appetite 16 (8) 3 (1) 1 (, 1) 20 (10)
*That occurred in $ 10% of patients overall (as assessed by the investigator; N = 201).
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Given that osimertinib is effective in treating patients with
T790M-positive tumors and is a potent inhibitor of EGFR-
activating mutations, the drug is under evaluation in patients
with EGFR-TKI–naive advanced NSCLC. These studies will
help to determine whether the development of T790M can be
prevented and whether this approach is associated with a longer
PFS than observed with gefitinib, erlotinib, or afatinib. Pre-
liminary findings from a cohort of patients treated as part of the
phase I trial demonstrated an encouraging response rate of 77%
and a median PFS of 19.3 months.26 A randomized phase III
trial to compare osimertinib with gefitinib and erlotinib in
EGFR-TKI–naive advanced EGFRm NSCLC has completed
enrollment (FLAURA [Osimertinib Versus Gefitinib or Erlo-
tinib in Patients With Locally Advanced or Metastatic NSCLC];
NCT02296125). To date, the strategy of using a more potent
kinase inhibitor capable of overcoming resistance mechanisms
to existing kinase inhibitors as initial therapy, including alec-
tinib in ALK-rearranged NSCLC or nilotinib or dasatinib in
chronic myeloid leukemia, has resulted in improved patient
outcomes.27-29
In summary, the results from the AURA extension study
show that osimertinib 80 mg once daily provides high response
rates, encouraging PFS, and a long DoR with a manageable safety
profile in patients with T790M-positive pretreated advanced
NSCLC.
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Appendix
Study Design and Participants
Eligibility criteria included the prospective confirmation of EGFR T790Mmutation status by a central laboratory that used the
cobas EGFRMutation Test (RocheMolecular Systems, Pleasanton, CA) from a tissue biopsy specimen taken after confirmed disease
progression while receiving the most recent treatment regimen (irrespective of whether epidermal growth factor receptor [EGFR]
tyrosine kinase inhibitor [TKI] or chemotherapy), a WHO performance status of 0 to 1, acceptable organ function, and at least one
measurable lesion not previously irradiated or chosen for biopsy during study screening. Patients with spinal cord compression or
brain metastases could be enrolled if the disease was asymptomatic, stable, and not requiring corticosteroids for at least 4 weeks
before first dose of study treatment.
Patients were excluded from the study if they had received treatment with an EGFR-TKI within 8 days or 5 half-lives of the first
dose of study treatment; chemotherapy, investigational agents, or other anticancer drugs from a previous regimen within 14 days of
the first dose of study treatment and medications or supplements known to inhibit cytochrome P450 isoenzyme 2C8 and inhibitors
or inducers of cytochrome P450 isoenzyme 3A4 within 7 days of the first dose of study treatment. Patients with unresolved toxicity
from prior treatment of more than National Cancer Institute Common Terminology Criteria for Adverse Events (version 4) grade 1
were excluded. Patients with a medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that
required corticosteroid treatment, or any evidence of clinically active ILD also were excluded.
cobas EGFR Mutation Test
The limit of detection for EGFRT790Mdetectionwith the cobas EGFRMutation Test version 1 is 2.04% (O’Donnell et al: BMC
Cancer 13:210, 2013). Compared with next-generation sequencing (two-tube amplicon assay run on MiSeq, read depth 35,000;
Roche Molecular Systems), positive and negative percent agreements for EGFR T790M detection were 91% and 97%, respectively
(Appendix Table A5, online only).
Procedures
If a patient experienced a Common Terminology Criteria for Adverse Events (version 4) grade 3 or an unacceptable adverse
event, osimertinib dosing was interrupted for up to 21 days. If the toxicity resolved to grade # 2 within 21 days and the patient
showed clinical benefit, treatment could be restarted at the same or lower dose of 40 mg/day. Patients with persistent QTc
prolongation for . 21 days or ILD were permanently withdrawn from study treatment but followed up postdiscontinuation for
disease progression.
Patient-reported outcomes were collected by using the European Organization for Research and Treatment of Cancer
questionnaires QLQ-LC13 (disease-specific symptoms) and QLQ-C30 (general cancer symptoms, functioning, and global health
status/quality of life) completed at baseline and then every 6 weeks.
Definitions of Progression-Free Survival and Duration of Response
Progression-free survival was defined as the time from date of first dose until the date of objective disease progression or death,
regardless of whether the patient withdrew from study treatment or received another anticancer therapy before progression.
Duration of response was defined as the time from date of first documented response (subsequently confirmed) until date of
documented progression or death in the absence of disease progression.
jco.org © 2017 by American Society of Clinical Oncology
AURA Phase II Extension
Downloaded from ascopubs.org by Universita Studi Di Torino on February 27, 2017 from 130.192.222.113
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Ov
er
al
l S
ur
vi
va
l (
pr
ob
ab
ili
ty
)
0
0.2
0.4
0.6
0.8
1.0
Time Since First Dose (months)
3 6 9 12 15 18
No. at risk
61 547505657Second line
140 53103113128134Third line or more
201 58150163184191Total
Second line
Third line or more
Total
Fig A1. Overall survival by line of therapy.
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Table A1. EGFR Mutations Detected by Last Prior EGFR-TKI Treatment (by Central cobas EGFR Mutation Test)
Mutation
Last Prior Treatment, No. (%; 95% CI)
Afatinib Erlotinib Gefitinib
No. of patients (N = 225) 31 109 85
T790M 21 of 31 (68; 49 to 83) 74 of 109 (68; 58 to 77) 59 of 85 (69; 59 to 79)
T790M + exon 19 deletion 14 of 21 (67; 43 to 85) 54 of 74 (73; 61 to 83) 42 of 59 (71; 58 to 82)
T790M + L858R 5 of 21 (24; 8 to 47) 17 of 74 (23; 14 to 34) 17 of 59 (29; 18 to 42)
T790M + G719X 0 of 21 (0; 0 to 16) 2 of 74 (3; , 1 to 9) 1 of 59 (2; , 1 to 9)
T790M + other/unknown EGFRm 0 of 21 (0; 0 to 16) 1 of 74 (1; , 1 to 7) 1 of 59 (2; , 1 to 9)
T790M only 2 of 21 (10; 1 to 30) 2 of 74 (3; , 1 to 9) 0 of 59 (0; 0 to 6)
T790M not detected 10 of 31 (32; 17 to 51) 35 of 109 (32; 24 to 42) 26 of 85 (31; 21 to 42)
Exon 19 deletion without T790M 5 of 10 (50; 19 to 81) 16 of 35 (46; 29 to 63) 12 of 26 (46; 27 to 67)
L858R without T790M 4 of 10 (40; 12 to 74) 13 of 35 (37; 22 to 55) 11 of 26 (42; 23 to 63)
G719X without T790M 0 of 10 (0; 0 to 31) 0 of 35 (0; 0 to 10) 1 of 26 (4; , 1 to 20)
Other/unknown EGFRm without T790M 2 of 10 (20; 3 to 56) 0 of 35 (0; 0 to 10) 1 of 26 (4; , 1 to 20)
Abbreviation: EGFRm, EGFR mutation.
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Table A2. Subset Analysis of Median PFS by Blinded Independent Central
Review (full analysis set)
Patient Characteristic
Median PFS,
Months (95% CI)
Sex
Male (n = 68) 12.5 (9.6 to NC)
Female (n = 133) 11.0 (8.1 to 15.5)
Age at screening, years
, 65 (n = 116) 11.7 (8.2 to 13.7)
$ 65 (n = 85) 12.5 (7.0 to 16.6)
Smoking status
Never (n = 134) 12.5 (9.5 to NC)
Ever* (n = 67) 12.3 (6.9 to 13.8)
Last treatment before osimertinib
EGFR-TKI (n = 159) 12.3 (8.1 to 13.8)
Non–EGFR-TKI (n = 42) 12.5 (7.1 to 15.5)
Immediate prior EGFR-TKI treatment
, 30 days before osimertinib (n = 105) 11.0 (6.9 to 17.0)
$ 30 days before osimertinib (n = 54) 12.5 (8.1 to NC)
Duration of most recent EGFR-TKI treatment
, 6 months (n = 43) 9.5 (4.2 to 13.7)
$ 6 months (n = 158) 12.4 (9.7 to NC)
NOTE. Calculated by Kaplan-Meier technique.
Abbreviations: EGFR, epidermal growth factor receptor; NC, not calculable;
PFS, progression-free survival; TKI, tyrosine kinase inhibitor.
*Current and former options are combined in the ever category.
Table A3. Safety Summary by AE Category
AE Category* No. (%)†
No. of patients 201
Any AE 199 (99)
Any possibly causally related AE‡ 185 (92)
Any grade $ 3 AE 77 (38)
Any grade $ 3 possibly causally related AE‡ 30 (15)
Any AE with outcome of death 7 (3)
Any possibly causally related AE with outcome of death‡ 3 (1)
Any SAE (including events with outcome of death) 55 (27)
Any possibly causally related SAE (including events with
outcome of death)‡
12 (6)
Any AE that led to interruption of osimertinib 43 (21)
Any AE that led to reduction of osimertinib 10 (5)
Any AE that led to discontinuation of osimertinib 15 (7)
Any possibly causally related AE that led to discontinuation of
osimertinib‡
9 (4)
Abbreviations: AE, adverse event; SAE, serious adverse event.
*Includes adverse events with an onset date on or after the date of first dose
and up to and including 28 days following the date of the last dose of study
medication.
†Patients with multiple events in the same category are counted only once in
that category. Patients with events in more than one category are counted once
in each of those categories.
‡As assessed by the investigator.
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Table A4. Safety Summary by Most Common AEs (all causality) That Occurred in $ 10% of Patients Overall
AE*
Grade, No. (%)
1 2 $ 3 Total (N = 201)
Diarrhea† 78 (39) 16 (8) 2 (1) 97 (48)§
Rash (grouped terms) 74 (37) 14 (7) 1 (, 1) 89 (44)
Dry skin (grouped terms) 60 (30) 7 (3) 0 67 (33)
Paronychia (grouped terms) 47 (23) 18 (9) 0 65 (32)
Decreased appetite 32 (16) 8 (4) 2 (1) 42 (21)
Cough 35 (17) 6 (3) 0 41 (20)
Nausea 30 (15) 8 (4) 3 (1) 41 (20)
Constipation 31 (15) 7 (3) 1 (, 1) 39 (19)
Back pain 26 (13) 8 (4) 1 (, 1) 35 (17)
Stomatitis 26 (13) 6 (3) 0 32 (16)
Platelet count decreased 26 (13) 3 (1) 2 (1) 31 (15)
Pruritus 25 (12) 6 (3) 0 31 (15)
Anemia 13 (6) 10 (5) 7 (3) 30 (15)
Fatigue 14 (7) 12 (6) 2 (1) 28 (14)
Vomiting 20 (10) 5 (2) 3 (1) 28 (14)
Headache 25 (12) 1 (, 1) 1 (, 1) 27 (13)
Asthenia 12 (6) 7 (3) 5 (2) 24 (12)
Dyspnea 12 (6) 7 (3) 5 (2) 24 (12)
Insomnia 20 (10) 4 (2) 0 24 (12)
Upper respiratory infection 16 (8) 8 (4) 0 24 (12)
Abbreviations: AE, adverse event.
*Includes AEswith an onset date on or after the date of first dose of studymedication and up to and including 28 days after the date of the last dose of studymedication.
†The grade of diarrhea in one patient was unknown.
Table A5. Concordance Data Between cobas EGFRMutation Test Version 1 and Next-Generation Sequencing for the Detection of EGFR T790M From Tissue Samples
Test Result
Next-Generation Sequencing,* No.
Positive Negative Invalid No Sample Total
cobas
Positive 190 3 0 14 207
Negative 18 82 0 17 117
Invalid 0 0 0 3 3
No sample 0 0 0 74 74
Total 208 85 0 108 401
Without invalid results, % (95% CI)
Positive percent agreement 91 (87 to 95)
Negative percent agreement 97 (90 to 99)
Overall percent agreement 93 (89 to 96)
*Two-tube amplicon assay run on MiSeq, read depth 35,000 (Roche Molecular Systems, Pleasanton, CA).
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